Valuation dashboard for ProPhase Labs, Inc. (PRPH) with P/E N/A, P/B -0.06, EV/EBITDA -1.31 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services.
Analysis Summary
ProPhase Labs, Inc. reported revenue of $4.3M in the most recent fiscal year, growing at a 5-year CAGR of -21.4%.
Trailing-twelve-month margins: gross margin 16.4%, operating margin -498.7%, net margin -7.2%.
At the current price of $0.01, PRPH has negative trailing earnings (P/E not meaningful) and an ROE of -13.59%. Market capitalisation stands at $0M.
Balance sheet quality for PRPH: current ratio of 0.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -0.06 |
| EV / EBITDA | -1.31 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-1.83 |
| vs Current Price | -13087.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PRPH | ProPhase Labs, Inc. | -13.6% | |||
| RPRX | Royalty Pharma plc | $25.9B | 24.26 | 3.81 | 12.3% |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $11.7B | 217.89 | 16.92 | 8.4% |
| LQDA | Liquidia Corporation | $6.1B | 42.09 | 30.09 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.9B | 72.84 | 9.24 | 13.7% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | 19.37 | -12.0% | |
| PBH | Prestige Consumer Healthcare Inc. | $2.2B | 13.34 | 1.19 | 9.2% |
Price
| Price | $0.01 |
| Market Cap | $0M |
| Exchange | OTC |
| Country | US |
Profitability
| Return on Equity | -1358.66% |
| Return on Invested Capital | -188.35% |
| Return on Assets | -39.44% |
| Gross Margin | 16.38% |
| Operating Margin | -498.73% |
| Net Margin | -717.43% |
Related companies: ADAP · AEMD · ALUR · AYTU · BFRI · CODX · ERNA
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of PRPH: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks